Conference Call with Alivus Life Sciences Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Alivus Life Sciences announced Q3FY26 results Revenue from operations of Rs 6,729 million, the highest ever quarterly revenues. This marks a growth of 14.4% QoQ and 4.8% YoY. EBITDA was at Rs 2,452 million, a growth of 26.5% QoQ and 22.1% YoY. EBITDA margins were at record high at 36.4%, up 340 bps QoQ and 510 bps YoY. PAT for Q3FY26 stood at Rs 1,503 million, a growth of 15.5% QoQ and 9.7% YoY. PAT margins were at 22.3%, up 100 bps YoY. Yasir Rawjee, MD & CEO, Alivus Life Sciences, said: “This quarter showed a clear improvement in our operating performance. The CDMO business recovered as expected, delivering the turnaround we had planned for in the second half of the year. We also saw robust growth in Non-GPL business especially across our key markets, including Europe, Japan, LATAM, ROW, and India, which collectively grew by 16% YoY during 9MFY26, in-line with our guidance. For full year, we expect Non-GPL to sustain its growth momentum, reinforcing our confidence in delivering high single-digit revenue growth for FY26. Driven by the strength of our core business and increased contributions from new product launches, we remain confident of sustaining margin expansion in the current year. Our focus continues to be on building a sustainable, long-term business through high-quality offerings, innovation, and scalable operations.” Tushar Mistry, CFO, Alivus Life Sciences, said: “Our focus on disciplined and sustainable growth translated into a strong performance this quarter, with revenues reaching Rs 6,729 million. This was accompanied by an EBITDA margin of 36.4%, the highest we have achieved so far, reflecting the strength of our diversified product portfolio and continued improvements in operational efficiency. We also remain in a strong financial position, operating as a net debt-free company. Generated free cash flow of Rs 2,207 million during 9MFY26, and cash and cash equivalents were at Rs 7,330 million as of 31st December 2025.” Result PDF